Statement on FDA’s Final Guidance Delay for Lab-Developed Tests

Senate health committee Chairman Lamar Alexander weighs in on FDA pushing final guidance to next administration.

Chairman Alexander / Photo: Getty Images
Chairman Alexander / Photo: Getty Images

On November 18th, Lamar Alexander, Chairman of the Senate health committee, gave a statement regarding the FDA’s decision to delay making final guidance on lab-developed tests:

“I am glad that the FDA has listened and will delay making final its current draft guidance that could have halted more than 60,000 lab-developed tests in their tracks, and will work with Congress and the new administration on next steps. These tests are essential to helping millions of Americans screen for and diagnose diseases and conditions and advancing the president’s Precision Medicine Initiative to find more tailored treatments and cures. It is important to get this right.”

Click here to see this and other statements from Chairman Alexander.

List: Digitalization Companies From PACK EXPO
Looking for CPG-focused digital transformation solutions? Download our editor-curated list from PACK EXPO featuring top companies offering warehouse management, ERP, digital twin, and MES software with supply chain visibility and analytics capabilities—all tailored specifically for CPG operations.
Download Now
List: Digitalization Companies From PACK EXPO
Pharmaceutical Innovations Report
Discover the latest breakthrough packaging technologies shaping the pharmaceutical sector. This report dives into cutting-edge innovations, from smart containers that enhance patient safety to eco-friendly materials poised to transform the industry’s sustainability practices. All from PACK EXPO. Learn how forward-thinking strategies are driving efficiency and redefining what’s possible in pharma packaging.
Learn More
Pharmaceutical Innovations Report